Epigral
Ticker >

Epigral share price

Epigral Ltd.

NSE: EPIGRAL BSE: 543332 SECTOR: Chemicals  58k   173   38

1319.70
+0.60 (0.05%)
BSE: 19 Apr 04:01 PM

Price Summary

Today's High

₹ 1325.95

Today's Low

₹ 1258.1

52 Week High

₹ 1401.35

52 Week Low

₹ 870

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 5483.37 Cr.

Enterprise Value

₹ 6344.46 Cr.

No. of Shares

4.16 Cr.

P/E

27.99

P/B

4.65

Face Value

₹ 10

Div. Yield

0.38 %

Book Value (TTM)

₹  283.52

CASH

₹ 15.06 Cr.

DEBT

₹ 876.14 Cr.

Promoter Holding

71.38 %

EPS (TTM)

₹  47.15

Sales Growth

41.1%

ROE

39.37 %

ROCE

32.2%

Profit Growth

39.78 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year41.1%
3 Year53.04%
5 Year29.64%

Profit Growth

1 Year39.78%
3 Year46.67%
5 Year17.84%

ROE%

1 Year39.37%
3 Year35.12%
5 Year37.07%

ROCE %

1 Year32.2%
3 Year26.12%
5 Year26.23%

Debt/Equity

0.8195

Price to Cash Flow

8.76

Interest Cover Ratio

8.82073222386695

CFO/PAT (5 Yr. Avg.)

1.56243162849142

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 71.38 0
Sep 2023 71.38 0
Jun 2023 71.37 0
Mar 2023 71.34 0
Dec 2022 71.21 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 46.667898680995% for the Past 3 years.
  • The company has shown a good revenue growth of 53.0418889533375% for the Past 3 years.
  • Company has been maintaining healthy ROE of 35.1245907222123% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.1160804946705% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 8.82073222386695.
  • The Company has been maintaining an effective average operating margins of 33.1060561641655% in the last 5 years.
  • Company’s PEG ratio is 0.70348502515811.
  • The company has an efficient Cash Conversion Cycle of 29.6309879942877 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.56243162849142.
  • The company has a high promoter holding of 71.38%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 537.84 562.18 454.89 478.15 471.52
Total Expenditure 371.32 407.46 359.7 370.29 348.75
Operating Profit 166.53 154.71 95.19 107.86 122.77
Other Income -0.26 4.54 1.52 1 2.46
Interest 21.03 18.99 18.34 21.27 20.19
Depreciation 30.84 30.13 30.8 31.51 30.88
Exceptional Items 0 0 0 0 0
Profit Before Tax 114.4 110.13 47.58 56.08 74.16
Tax 37.2 33.33 15.9 17.95 24.85
Profit After Tax 77.2 76.8 31.68 38.13 49.31
Adjusted EPS (Rs) 18.58 18.48 7.62 9.18 11.87

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 710.39 610.51 828.6 1550.94 2188.4
Total Expenditure 398.71 416.38 567.27 1041.45 1499.4
Operating Profit 311.68 194.13 261.33 509.49 689
Other Income 14.26 8.55 7.47 8.34 9.29
Interest 29.55 17.38 34.4 48.5 66.81
Depreciation 54.1 44.3 73.54 85.91 108.95
Exceptional Items 0 0 0 0 0
Profit Before Tax 242.29 140.99 160.86 383.42 522.53
Tax 59.48 29 60.02 130.64 169.17
Net Profit 182.81 112 100.84 252.79 353.36
Adjusted EPS (Rs.) 44.38 26.95 24.27 60.84 85.04

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 252.11 252.47 252.47 41.55 41.55
Total Reserves 240.66 331 431.66 684.42 1027.62
Borrowings 365.34 418.29 340.47 768.14 544.64
Other N/C liabilities 8.65 5.94 35.49 97.26 170.8
Current liabilities 177.17 264.82 388.66 532.29 647.64
Total Liabilities 1043.93 1272.51 1448.75 2123.67 2432.25
Assets
Net Block 294.72 440.17 1102.31 1067.83 1804.05
Capital WIP 468.25 691.16 125.84 589.25 158.1
Intangible WIP 0 0 0 0 0
Investments 0 0 0.05 0.05 20.62
Loans & Advances 23.39 7.46 35.02 17.85 29.6
Other N/C Assets 3.26 1.64 4.24 1.79 0.44
Current Assets 254.32 132.08 181.29 446.89 419.45
Total Assets 1043.93 1272.51 1448.75 2123.67 2432.25
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 242.29 140.99 160.86 383.42 522.53
Adjustment 69.81 55.85 102.62 130.25 170.35
Changes in Assets & Liabilities 8.05 -3.81 -5.65 -169.41 40.77
Tax Paid -58.81 -28.35 -28.62 -60.45 -107.48
Operating Cash Flow 261.35 164.68 229.22 283.82 626.16
Investing Cash Flow -217.3 -363.21 -196.73 -454.68 -437.22
Financing Cash Flow 85.09 69.41 -31.9 195.22 -199.79
Net Cash Flow 129.14 -129.12 0.58 24.36 -10.85

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 71.21 71.34 71.37 71.38 71.38
adesh k patel 0.03 0.03 0.03 0.03 0.03
amrutbhai shivrambhai pat... - - - - 0.01
anand i patel (huf) 0.09 0.09 0.09 0.09 0.09
anandbhai ishwarbhai pate... 4.37 4.37 4.37 4.37 4.37
ashishbhai natawarlal sop... 11.12 11.12 11.12 11.12 11.12
ashishbhai soparkar (huf)... 0.03 0.03 0.03 0.03 0.03
bhartiben natubhai patel 1.01 1.01 1.01 1.01 1.01
chintan anandbhai patel 0.98 0.98 0.98 0.98 0.98
deval a soparkar 0.48 0.48 0.48 0.48 0.48
dhiren madhur goyal 0.02 0.02 0.02 0.02 0.02
disha kevatkumar vanani 1.17 1.17 1.17 1.17 1.17
hansaben amrutbhai patel 0.03 0.03 0.03 0.03 0.03
haribhai meghjibhai patel... 0.10 0.10 0.10 0.10 0.10
jagrutiben lalitbhai pate... 0.07 0.07 0.07 0.07 0.07
jayantibhai meghjibhai pa... 8.61 8.61 8.61 8.61 8.61
kantibhai meghjibhai pate... 0.16 0.16 0.16 0.16 0.16
kantibhai meghjibhai pate... 0.18 0.18 0.18 0.18 0.18
kaushal ashish soparkar 4.15 4.15 4.15 4.15 4.15
kruti adesh patel 0.87 0.88 0.88 0.88 0.88
maulik jayantibhai patel 5.08 5.18 5.18 5.18 5.18
nayanaben a soparkar 0.81 0.81 0.81 0.81 0.81
patel ankit natwarlal 4.61 4.61 4.61 4.61 4.61
patel damini narendra 0.03 0.03 0.03 0.03 0.03
patel darshan anandbhai 0.98 0.98 0.98 0.98 0.98
patel jayantibhai meghjib... 0.17 0.17 0.17 0.17 0.17
patel kalpana rameshbhai 1.32 1.32 1.32 1.32 1.32
patel karana rameshbhai 1.74 1.74 1.74 1.74 1.74
patel natubhai meghjibhai... 1.17 1.17 1.17 1.17 1.17
patel natwarlal meghjibha... 10.05 10.05 10.05 10.05 10.05
patel naynaben anandbhai... 0.40 0.40 0.40 0.41 0.41
patel rameshbhai meghjibh... 0.23 0.23 0.23 0.23 0.23
popatbhai m patel (huf) 0.06 0.06 0.06 0.06 0.06
popatbhai meghjibhai pate... 0.07 0.07 0.07 0.07 0.07
rameshbhai meghjibhai pat... 7.02 7.03 7.05 7.05 7.05
ruchi ashishbhai soparkar... 0.48 0.48 0.48 0.48 0.48
sandhya maulik patel 0.10 0.10 0.10 0.10 0.10
taraben jayantilal patel 2.43 2.43 2.43 2.43 2.43
vaishakhi dhiren goyal 1.01 1.01 1.01 1.01 1.01
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 28.79 28.66 28.63 28.62 28.62
investor education and pr... 0.03 0.03 - 0.03 0.03
llp 1.05 1.05 1.05 1.07 1.07
vls finance ltd - - 1.34 1.35 1.24
investor education and pr... - - 0.03 - -
vls finance limited 1.30 1.33 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Epigral commissions additional 45,000 TPA capacity of CPVC resin plant at Dahej facility3 Apr 2024, 3:37PM Epigral informs about press release 3 Apr 2024, 1:32PM Epigral informs about analyst meet2 Mar 2024, 3:24PM Epigral submits analyst meet intimation23 Feb 2024, 1:08PM Epigral - Quaterly Results24 Jan 2024, 12:48PM Epigral - Quaterly Results24 Jan 2024, 12:48PM Epigral - Quaterly Results24 Jan 2024, 12:48PM Epigral submits analyst meet intimation18 Jan 2024, 4:49PM Epigral informs about board meeting 2 Jan 2024, 12:47PM Epigral submits analyst meet intimation18 Dec 2023, 4:30PM Epigral opens first R&D Centre in Ahmedabad20 Nov 2023, 12:59PM Epigral informs about press release 20 Nov 2023, 12:41PM Epigral - Quaterly Results6 Nov 2023, 1:27PM Epigral - Quaterly Results6 Nov 2023, 1:27PM Epigral - Quaterly Results6 Nov 2023, 1:27PM Epigral informs about conference call30 Oct 2023, 2:28PM Meghmani Finechem informs about updates31 Aug 2023, 4:28PM Epigral to set-up CPVC compound manufacturing facility at Dahej31 Aug 2023, 12:25PM Meghmani Finechem - Quaterly Results5 Aug 2023, 1:53PM Meghmani Finechem - Quaterly Results5 Aug 2023, 1:53PM Meghmani Finechem - Quaterly Results5 Aug 2023, 1:53PM Meghmani Finechem commissions wind solar hybrid power plant27 Jun 2023, 6:08PM Meghmani Finechem informs about investor meet 20 Jun 2023, 2:06PM Meghmani Finechem informs about BRSR3 Jun 2023, 3:08PM Meghmani Finechem informs about record date and book closure date3 Jun 2023, 3:02PM Meghmani Finechem informs about audio recording of conference call26 Apr 2023, 10:05AM Meghmani Finechem reports 23% fall in Q4 consolidated net profit25 Apr 2023, 3:51PM Meghmani Finechem - Quaterly Results25 Apr 2023, 1:18PM Meghmani Finechem - Quaterly Results25 Apr 2023, 1:18PM Meghmani Finechem - Quaterly Results25 Apr 2023, 1:18PM Meghmani Finechem informs about trading window closure29 Mar 2023, 5:05PM Meghmani Finechem informs about investors pant visit25 Feb 2023, 11:54AM Meghmani Finechem informs about audio recording of earning call20 Jan 2023, 12:45PM Meghmani Finechem gets nod to expand production capacity of CPVC Resin plant19 Jan 2023, 5:51PM Meghmani Finechem informs about record date for payment of dividend19 Jan 2023, 5:05PM Meghmani Finechem - Quaterly Results19 Jan 2023, 1:38PM Meghmani Finechem - Quaterly Results19 Jan 2023, 1:38PM Meghmani Finechem - Quaterly Results19 Jan 2023, 1:38PM Meghmani Finechem informs about board meeting 11 Jan 2023, 4:49PM Meghmani Finechem informs about investor meet 22 Dec 2022, 3:59PM Meghmani Finechem informs about analyst meet intimation19 Dec 2022, 4:28PM Meghmani Finechem informs about analyst meet intimation3 Dec 2022, 2:46PM Meghmani Finechem informs about analyst meet intimation27 Oct 2022, 5:04PM Meghmani Finechem informs about outcome of board meeting20 Oct 2022, 5:00PM Meghmani Finechem - Quaterly Results20 Oct 2022, 1:47PM Meghmani Finechem - Quaterly Results20 Oct 2022, 1:47PM Meghmani Finechem - Quaterly Results20 Oct 2022, 1:47PM Meghmani Finechem acquires immovable property in Dahej3 Oct 2022, 2:58PM Meghmani Finechem commissions additional capacity of Caustic Soda at Dahej30 Sep 2022, 10:30AM Meghmani Finechem informs about investors meet23 Sep 2022, 12:51PM

Epigral Stock Price Analysis and Quick Research Report. Is Epigral an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a LOW P/E are undervalued (it depends on other factors too). Epigral has a PE ratio of 27.9879709198259 which is high and comparatively overvalued .

  • Share Price: - The current share price of Epigral is Rs 1319.7. One can use valuation calculators of ticker to know if Epigral share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Epigral has ROA of 15.5120205840386 % which is a good sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Epigral has a Current ratio of 0.647657612518056 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Epigral has a ROE of 39.3683132525959 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Epigral has a D/E ratio of 0.8195 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Epigral has an Inventory turnover ratio of 12.6673905933074 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Epigral has reported revenue growth of 41.1013788141834 % which is fair in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Epigral for the current financial year is 31.4840748698695 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Epigral is Rs 5 and the yield is 0.3793 %.

Last Updated on:
Brief about Epigral

Epigral Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Epigral Ltd. is a renowned pharmaceutical and biotech company based in the United States. The company specializes in developing innovative products and solutions for healthcare needs. With over 10,000 employees worldwide, Epigral Ltd. has emerged as a trusted healthcare partner for millions of people worldwide.

The company's mission is to enable access to high-quality healthcare services, ensuring impactful outcomes and improving patient health. Epigral Ltd. is known for its R&D capabilities and a robust product pipeline that demonstrates its commitment to innovation and excellence.

Epigral Ltd. - Share Price

At present, Epigral Ltd. is trading at a healthy share price, reflecting the company's consistent financial performance and promising growth prospects. Investors looking for a long-term investment opportunity can add Epigral Ltd. stock to their portfolio.

Our pre-built screening tools can help investors analyze the stock's performance based on various parameters and identify investment opportunities accordingly.

Epigral Ltd. - Balance Sheet

Epigral Ltd.'s annual reports can provide investors with valuable insights into the company's financial health. The balance sheet section of the report is particularly critical as it highlights the company's assets, liabilities, and equity.

Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis and investors can make informed decisions based on the calculations.

Epigral Ltd. - Annual Report

Epigral Ltd.'s annual report is a comprehensive document that provides a detailed analysis of the company's financial performance over the past year. This report includes financial statements, management commentary, and discussions about the company's operations, accomplishments, and long-term objectives.

Investors looking for detailed insights into Epigral Ltd.'s financial performance can download this report from our website.

Epigral Ltd. - Dividend

Epigral Ltd. is a company that believes in rewarding its shareholders. The company offers attractive dividends to its investors, making it an ideal investment opportunity for those looking for steady returns.

Investors can track the company's dividend history and current dividend yield using various tools available on our website.

Epigral Ltd. - Quarterly Result

Epigral Ltd.'s quarterly results provide a snapshot of the company's financial performance for a particular quarter. Investors can use this information to assess the company's short-term performance and identify trends.

Our pre-built screening tools can help investors stay updated with the company's performance as we provide quarterly result updates on our website.

Epigral Ltd. - Stock Price

Epigral Ltd.'s stock price is a crucial metric that can help investors gauge the company's performance and growth prospects. Our website offers a comprehensive analysis of the stock price, including historical data and charts that provide insights into the stock's trend.

Investors can use our pre-built screening tools and analytics to track the stock's performance and identify long-term investment opportunities.

Epigral Ltd. - Price Chart

Epigral Ltd.'s price chart provides a detailed analysis of the stock's performance over time. The chart tracks the stock's price movements, highs, lows, and other essential details that can help investors assess the long-term potential of the stock.

Investors can use our price chart analysis tools to track the stock's performance and make informed investment decisions.

Epigral Ltd. - News

Epigral Ltd.'s news section on our website provides investors with the latest updates and news concerning the company's operations and performance. This section covers a wide range of topics, including product launches, financial results, partnerships, and more.

Investors can stay updated by following our news section and analyzing the news's impact on the stock's performance.

Epigral Ltd. - Concall Transcripts

Epigral Ltd.'s concall transcripts provide investors with valuable insights into the company's performance, operations, and management's future plan. These transcripts are available for download on our website.

Epigral Ltd. - Investor Presentations

Epigral Ltd.'s investor presentations are an excellent resource for investors to learn more about the company, its future plans, and opportunities. These presentations provide investors with detailed analysis and insights into Epigral Ltd.'s business strategy and operations.

Epigral Ltd. - Promoters

Epigral Ltd.'s promoters are seasoned professionals with a deep understanding of the healthcare industry and Epigral Ltd.'s operations. The company's management team has a wealth of experience, which adds value to Epigral Ltd.'s operations and future growth prospects.

Epigral Ltd. - Shareholders

Epigral Ltd.'s shareholders play a critical role in the company's decision-making process. The company has a robust shareholder engagement program, ensuring that shareholders are updated regarding the company's operations and financial performance.

Conclusion:

We have outlined the crucial aspects of Epigral Ltd.'s stock analysis page, which can help investors make informed investment decisions. Epigral Ltd.'s reputation as a trusted healthcare partner, a consistent financial performance, and a promising growth prospect builds a strong case for long-term investment opportunities. Our website's pre-built screening tools and premium features such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable investors to make informed investment decisions. Downloadable documents such as annual reports, concall transcripts, investor presentations, credit ratings, and research reports are available on our website, making it an excellent resource for investors.

Read More
X